1. Home
  2. CPBI vs MNOV Comparison

CPBI vs MNOV Comparison

Compare CPBI & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$18.38

Market Cap

73.5M

Sector

N/A

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.35

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPBI
MNOV
Founded
2023
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.5M
69.4M
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
CPBI
MNOV
Price
$18.38
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
4.9K
22.0K
Earning Date
06-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$180.00
P/E Ratio
$22.98
N/A
Revenue Growth
N/A
194.15
52 Week Low
$14.52
$1.17
52 Week High
$18.75
$1.96

Technical Indicators

Market Signals
Indicator
CPBI
MNOV
Relative Strength Index (RSI) 63.80 45.49
Support Level $16.88 $1.35
Resistance Level N/A $1.43
Average True Range (ATR) 0.17 0.03
MACD 0.09 -0.00
Stochastic Oscillator 74.29 43.33

Price Performance

Historical Comparison
CPBI
MNOV

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: